Clinical trial · Observational
Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting
Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - CombHADom
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy-chemotherapy combo for bronchial cancer in maintenance phase of first row metastatic treatment. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated. A cost-benefit analysis will be done to compare hospital-at-home programme and classical day hospitalization.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bronchial Cancer | Bronchogenic Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| home-based hospitalization | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)
- timeFrame
- 1 year
- description
- Feasibility under good conditions of home-based immunotherapy, defined by the percentage of patients who interrupted their home hospitalization for reasons directly linked to that management.
Secondary outcomes (6)
- measure
- Cost-benefit analysis
- timeFrame
- 1 year
- description
- A cost-benefit analysis comparing hospital-at-home programme and classical day hospitalization
- measure
- Number of adverse effects occuring during the study
- timeFrame
- 1 year
- description
- Immunotherapy related adverse effects monitoring criteria evaluation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 and over, * with bronchial metastatic cancer treated in first row maintenance phase by immunotherapy-chemotherapy combo, * having at least one assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response), * without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy * eligible for a home-based hospitalization Exclusion Criteria: * Frail patients requiring a frequent medical assessment thus day hospitalization cares
References
Publications (0)
Data not yet available